Literature DB >> 31283416

Rapidly Changing Landscape of Fallopian Tube Carcinoma.

Katherine C Kurnit1, Karen H Lu1, Shannon N Westin1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31283416      PMCID： PMC6881185          DOI： 10.1200/JOP.19.00248

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.714


× No keyword cloud information.
  11 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Fallopian Tube Carcinoma.

Authors:  Marina Stasenko; Olga Fillipova; William P Tew
Journal:  J Oncol Pract       Date:  2019-07-08       Impact factor: 3.840

6.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

7.  Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.

Authors:  Johnathan M Lancaster; C Bethan Powell; Lee-May Chen; Debra L Richardson
Journal:  Gynecol Oncol       Date:  2014-09-17       Impact factor: 5.482

8.  Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.

Authors:  John K Chan; Thomas J Herzog; Lilian Hu; Bradley J Monk; Tuyen Kiet; Kevin Blansit; Daniel S Kapp; Xinhua Yu
Journal:  Oncologist       Date:  2014-04-10

9.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

10.  Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.

Authors:  Sue V Petzel; Rachel Isaksson Vogel; Jena McNiel; Anna Leininger; Peter A Argenta; Melissa A Geller
Journal:  Int J Gynecol Cancer       Date:  2014-07       Impact factor: 3.437
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.